{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:14:00Z","timestamp":1782602040939,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.leukres.2004.10.002","type":"journal-article","created":{"date-parts":[[2005,1,25]],"date-time":"2005-01-25T18:14:04Z","timestamp":1106676844000},"page":"481-491","source":"Crossref","is-referenced-by-count":73,"title":["Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders"],"prefix":"10.1016","volume":"29","author":[{"given":"Steven M.","family":"Fruchtman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Petitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet S.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrick","family":"Fiddler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2004.10.002_bib1","first-page":"17","article-title":"From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2004.10.002_bib2","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2004.10.002_bib3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2004.10.002_bib4","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood-2003-03-0919","article-title":"Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis","volume":"102","author":"Klippel","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2004.10.002_bib5","first-page":"231","article-title":"PRV-1 mRNA expression and other molecular markers in polycythemia rubra vera","volume":"2","author":"Pahl","year":"2003","journal-title":"Curr Hematol Rep"},{"key":"10.1016\/j.leukres.2004.10.002_bib6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2004.10.002_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s002770050536","article-title":"Treatment of essential thrombocythemia with special emphasis on leukemogenic risk","volume":"78","author":"Finazzi","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2004.10.002_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0037-1963(01)90137-4","article-title":"Current management in polycythemia vera","volume":"38","author":"Gilbert","year":"2001","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2004.10.002_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ajh.2830170402","article-title":"Treatment of polycythemia vera with hydroxyurea","volume":"17","author":"Donovan","year":"1984","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2004.10.002_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10375","article-title":"Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan","volume":"74","author":"Nielsen","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2004.10.002_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0369-8114(00)00024-9","article-title":"Efficacy and safety of hydroxyurea in patients with essential thrombocythemia","volume":"49","author":"Finazzi","year":"2001","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.leukres.2004.10.002_bib12","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2004.10.002_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1054\/blre.2001.0158","article-title":"Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management","volume":"15","author":"Tefferi","year":"2001","journal-title":"Blood Rev"},{"key":"10.1016\/j.leukres.2004.10.002_bib14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2004.10.002_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/10428199609074373","article-title":"Treatment strategies in essential thrombocythemia A critical appraisal of various experiences in different centers","volume":"22","author":"Barbui","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2004.10.002_bib16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/asheducation-2003.1.200","article-title":"Chronic myeloproliferative disorders","author":"Spivak","year":"2003","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2004.10.002_bib17","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/BF03165137","article-title":"Treatment of polycythemia vera with recombinant interferon","volume":"76","author":"Silver","year":"2002","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2004.10.002_bib18","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","article-title":"Long-term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy","volume":"83","author":"Gilbert","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2004.10.002_bib19","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJM198805193182002","article-title":"Anagrelide: a new drug for treating thrombocytosis","volume":"318","author":"Silverstein","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2004.10.002_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/10245330290028597","article-title":"Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide","volume":"7","author":"Andersson","year":"2002","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2004.10.002_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1034\/j.1600-0609.2000.90236.x","article-title":"Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area","volume":"65","author":"Jensen","year":"2000","journal-title":"Eur J Haematol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521260400373X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521260400373X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T12:18:59Z","timestamp":1586089139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521260400373X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S014521260400373X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2004.10.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}